A Comprehensive Review of Nonalcoholic Fatty Liver Disease: Epidemiology, Pathophysiology, Risk Factors, Clinical Features, Diagnosis, and Management Strategies

Abstract

Nonalcoholic fatty liver disease (NAFLD) has emerged as the most prevalent chronic liver disorder worldwide, paralleling the global epidemics of obesity and metabolic syndrome. Characterized by excessive hepatic fat accumulation in the absence of significant alcohol consumption, NAFLD encompasses a spectrum ranging from simple steatosis to nonalcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and hepatocellular carcinoma. This review synthesizes recent evidence on the epidemiology, pathophysiology, risk factors, clinical features, diagnosis, and management of NAFLD, emphasizing clinical relevance, mechanistic insights, and practical implications for healthcare professionals.

Introduction

NAFLD is defined by hepatic steatosis affecting more than 5% of hepatocytes, in individuals without significant alcohol intake or secondary causes of liver fat accumulation. Over the past two decades, its prevalence has surged, becoming a leading cause of chronic liver disease globally. NAFLD is not only a hepatic manifestation but also a systemic disorder with metabolic, cardiovascular, and oncologic implications. Understanding its pathophysiology and clinical spectrum is crucial for risk stratification and patient management.

Epidemiology / Disease Burden

Recent meta-analyses estimate the global prevalence of NAFLD at approximately 25%, with regional variation higher rates in the Middle East and South America, and lower in Africa. In Western countries, NAFLD affects nearly one in three adults, with rising incidence in pediatric populations. NASH, the progressive form, is present in 10–20% of NAFLD cases, and up to 30% may develop advanced fibrosis, cirrhosis, or hepatocellular carcinoma. NAFLD is now the leading indication for liver transplantation in the United States. Its escalating burden poses significant health and economic challenges, underscoring the urgency for early identification and intervention.

Pathophysiology

The pathogenesis of NAFLD is multifactorial, centering on insulin resistance, adipose tissue dysfunction, and a complex interplay of genetic, epigenetic, and environmental factors. The "multiple-hit" hypothesis supersedes the earlier "two-hit" model, recognizing the simultaneous contribution of metabolic derangements, lipotoxicity, oxidative stress, mitochondrial dysfunction, gut dysbiosis, and inflammatory cascades. Genetic polymorphisms, notably in PNPLA3 and TM6SF2, modulate susceptibility and disease progression. Hepatic steatosis results from an imbalance between lipid acquisition (increased de novo lipogenesis, free fatty acid influx) and disposal (impaired beta-oxidation, very-low-density lipoprotein secretion). Progression to NASH involves hepatocyte injury, inflammatory cell recruitment, and fibrogenesis.

Risk Factors

NAFLD is closely linked to components of the metabolic syndrome, including obesity (especially visceral adiposity), type 2 diabetes mellitus, dyslipidemia, and hypertension. Additional risk factors include polycystic ovary syndrome, obstructive sleep apnea, hypothyroidism, and sedentary lifestyle. Ethnicity modifies risk Hispanics show higher prevalence, while African Americans are relatively protected. Familial aggregation and genetic predisposition play significant roles. Notably, lean NAFLD is increasingly recognized, often associated with subtle metabolic derangements or sarcopenia.

Clinical Features

Most patients with NAFLD are asymptomatic, diagnosed incidentally via abnormal liver enzymes or imaging. When present, symptoms are nonspecific fatigue, right upper quadrant discomfort. Physical examination may reveal hepatomegaly. Advanced disease manifests with stigmata of chronic liver disease or portal hypertension. Importantly, NAFLD confers increased risk of cardiovascular disease, independent of traditional risk factors, and is associated with extrahepatic malignancies, chronic kidney disease, and endocrinopathies.

Diagnosis

Diagnosis of NAFLD requires demonstration of hepatic steatosis (imaging or histology), exclusion of significant alcohol use, and ruling out other causes of steatosis (e.g., viral hepatitis, medications, lipodystrophy). Ultrasound is the preferred initial screening tool, though limited in sensitivity at lower degrees of steatosis or in obese individuals. Advanced imaging modalities controlled attenuation parameter (CAP) via transient elastography, MRI-proton density fat fraction offer improved quantification. Liver biopsy remains the gold standard for grading steatosis, inflammation, and fibrosis, but is reserved for selected cases due to invasiveness. Noninvasive fibrosis assessment (e.g., FIB-4, NAFLD fibrosis score, elastography) is recommended for risk stratification.

Treatment & Management

Lifestyle modification is the cornerstone of NAFLD management. Sustained weight loss of 7–10% correlates with histological improvement, including NASH resolution and fibrosis regression. Dietary interventions (caloric restriction, Mediterranean diet, reducing fructose intake), increased physical activity, and behavioral therapy are foundational. Pharmacologic therapy is considered in biopsy-proven NASH or advanced fibrosis: pioglitazone and vitamin E have demonstrated efficacy in select populations. Management of comorbidities glycemic control, lipid lowering, blood pressure optimization is essential. Bariatric surgery is an option for eligible patients with severe obesity and NAFLD.

Recent Advances / Emerging Therapies

Research into the molecular pathogenesis of NAFLD has spurred development of targeted therapies. Agents under investigation include GLP-1 receptor agonists (semaglutide, liraglutide), SGLT2 inhibitors, FXR agonists (obeticholic acid), PPAR agonists, and anti-fibrotic agents. Early trials show promise in reducing hepatic steatosis, NASH activity, and fibrosis, though long-term safety and efficacy data are awaited. Noninvasive biomarkers and imaging modalities are being refined to enhance risk stratification and monitor therapeutic response.

Guideline Recommendations

Society guidelines (AASLD, EASL, APASL) recommend opportunistic screening for NAFLD in high-risk groups (obesity, diabetes), risk stratification using noninvasive fibrosis tools, and prioritization of lifestyle interventions. Pharmacotherapy is reserved for biopsy-confirmed NASH with fibrosis. Routine surveillance for hepatocellular carcinoma is advised in cirrhotic NAFLD patients. Holistic care addressing cardiovascular risk factors is emphasized, given the leading cause of mortality in NAFLD is cardiovascular disease rather than liver-related events.

Conclusion

NAFLD represents a major global health concern with significant hepatic and extrahepatic morbidity and mortality. A nuanced understanding of its epidemiology, pathophysiology, risk factors, and clinical spectrum is essential for early identification and targeted management. While lifestyle modification remains the mainstay, emerging pharmacotherapies and noninvasive diagnostic modalities hold promise for transforming NAFLD care. Multidisciplinary, guideline-based approaches are vital for mitigating disease burden and improving patient outcomes.